IMV Inc. (IMV) News
Filter IMV News Items
IMV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMV News Highlights
- IMV's 30 day story count now stands at 4.
- Over the past 7 days, the trend for IMV's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- NOVA, HRZN and ACT are the most mentioned tickers in articles about IMV.
Latest IMV News From Around the Web
Below are the latest news stories about IMV INC that investors may wish to consider to help them evaluate IMV as an investment opportunity.
IMV Receives NASDAQ Delisting NoticeDARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 08, 2023--IMV Inc. (the "Company" or "IMV") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exerci |
Horizon Technology Finance Announces First Quarter 2023 Financial ResultsHorizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the first quarter ended March 31, 2023. |
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic AlternativesDARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 01, 2023--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act |
IIROC Trading Halt - IMVThe following issues have been halted by IIROC: |
IMV Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyDARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 31, 2023--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company’s |
IMV Inc. Announces Changes to Its Board of DirectorsDARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 27, 2023--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective immediately. |
IMV Inc. (NASDAQ:IMV) Q4 2022 Earnings Call TranscriptIMV Inc. (NASDAQ:IMV) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good day and thank you for standing by. Welcome to IMV’s Fourth Quarter and Fiscal Year 2022 Results Webcast. Please be advised that today’s conference is being recorded. I would now like to turn the conference over to Mr. Andrew Hall, Chief Executive […] |
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational ResultsDARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 16, 2023--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced alongside the release of its fourth quarter and annual results that it has engaged Stonegate Healthcare Partners, L.L.C ("Stonegate") to explore strategic alternatives following a review of its business. |
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 09, 2023--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results. |
IMV Stock Falls After Interim Data From Lead Candidate In Blood Cancer SubtypeIMV Inc (NASDAQ: IMV) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL). Related: IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti-Tumor Activity 8 Patients with an ECOG score of 0-1 have been enrolled in arm 1 of the study. Of these, six have so far been evaluable for efficacy; Of |